Patents by Inventor Liana Rosenthal

Liana Rosenthal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DETECTION OF PAR IN THE CSF OF PATIENTS WITH PARKINSON'S DISEASE
    Publication number: 20230176041
    Abstract: Poly(ADP-ribose) (PAR) is a protein implicated in numerous neurodegenerative disease states including Parkinson's disease (PD). To date, no routine laboratory test has been developed to diagnosis, assess or monitor patients suffering from PD. Disclosed herein a novel method to assess the PAR concentration in the cerebral spinal fluid (CSF) of a patient and correlate that concentration to the medical condition of a patient with PD. Also disclosed is the use of PAR as a biomarker for PD.
    Type: Application
    Filed: October 26, 2022
    Publication date: June 8, 2023
    Inventors: Ted Dawson, Valina Dawson, Tae-In Kam, Liana Rosenthal, Shaida Andrabi
  • BIOMARKERS FOR NEURODEGENERATIVE DISORDERS
    Publication number: 20220291240
    Abstract: The invention relates to methods for diagnosis, monitoring progression, and treatment of neurodegenerative disorders. In particular, biomarkers for diagnosis, monitoring progression, and treatment of neurodegenerative disorders are provided. In some embodiments, methods for diagnosis, monitoring progression, and treatment of synucleinopathies and related disorders are provided.
    Type: Application
    Filed: August 26, 2020
    Publication date: September 15, 2022
    Inventors: Ted M. Dawson, Liana Rosenthal, Saurav Brahmachari, Tae-In Kam, Valina L. Dawson
  • DETECTION OF PAR IN THE CSF OF PATIENTS WITH PARKINSON'S DISEASE
    Publication number: 20210148898
    Abstract: Poly(ADP-ribose) (PAR) is a protein implicated in numerous neurodegenerative disease states including Parkinson's disease (PD). To date, no routine laboratory test has been developed to diagnosis, assess or monitor patients suffering from PD. Disclosed herein a novel method to assess the PAR concentration in the cerebral spinal fluid (CSF) of a patient and correlate that concentration to the medical condition of a patient with PD. Also disclosed is the use of PAR as a biomarker for PD.
    Type: Application
    Filed: June 1, 2018
    Publication date: May 20, 2021
    Inventors: Ted Dawson, Valina Dawson, Tae-In Kam, Liana Rosenthal, Shaida Andrabi